Cover Image

Refractory facial cutaneous B-cell pseudolymphoma successfully treated with dupilumab

Saved in:

Bibliographic Details
Main Authors:	Kalisa Lum, BS (Author), Ruth Sanchez, BS (Author), Cici Zhou, MD (Author), Sophia Sangar, MD (Author), Harry Dao, Jr., MD (Author), Ashley Elsensohn, MD, MPH (Author)
Format:	Book
Published:	Elsevier, 2024-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Multifocal and recurrent cutaneous pseudolymphoma associated with lamotrigine and review of the literature
by: Soroush Kazemi, BS, et al.
Published: (2022)

A case of nonuremic calciphylaxis of the penis responding to sodium thiosulfate therapy
by: Kalisa Lum, BS, et al.
Published: (2023)

Cutaneous pseudolymphoma secondary to facial thread lift procedure
by: Meena Makhecha, et al.
Published: (2019)

A case of facial cutaneous B-cell pseudolymphoma
by: Junhao CHEN, et al.
Published: (2022)

Pseudolymphoma of the nipple treated with topical imiquimod and cryotherapy
by: Amy Xiao, BS, et al.
Published: (2022)

Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash
by: Nicholas A. Trum, BS, et al.
Published: (2021)

Can't handle the itch? Refractory immunotherapy-related transient acantholytic dermatosis: prompt resolution with dupilumab
by: Eva Shelton, BS, et al.
Published: (2022)

Cutaneous pseudolymphoma: An enigma
by: B M Shashikumar, et al.
Published: (2017)

Successful treatment of refractory subacute cutaneous lupus erythematosus with deucravacitinib
by: Nicole Bouché, BS, et al.
Published: (2023)

Alcohol-induced facial flushing in a patient with atopic dermatitis treated with dupilumab
by: Sean J. Igelman, BS, et al.
Published: (2020)

T-cell rich angiomatoid polypoid pseudolymphoma: A novel cutaneous pseudolymphoma
by: V Sandhya, et al.
Published: (2014)

Management of refractory pruritus in Alagille syndrome with dupilumab treatment: A case report
by: Daniel S. Alicea, MS, et al.
Published: (2024)

Six cases of refractory pruritus and histologic dermal hypersensitivity reaction successfully treated with dupilumab
by: Nicole Edmonds, BA, et al.
Published: (2022)

An unusual presentation of cutaneous pseudolymphoma
by: Ying Wang, et al.
Published: (2022)

Idiopathic cutaneous pseudolymphoma: An enigma
by: Vinod Prabhu, et al.
Published: (2014)

Paraphenylenediamine-induced cutaneous pseudolymphoma
by: Fiona F Sequeira, et al.
Published: (2014)

Oral, periorbital, and inguinal purpura in a patient with paraproteinemia
by: Donn LaTour, BS, et al.
Published: (2022)

Refractory pruritus responds to dupilumab in a patient with TTC7A mutation
by: Yassaman Alipour Tehrany, MD, et al.
Published: (2021)

Refractory granuloma faciale successfully treated with adjunct topical JAK inhibitor
by: Ailynna Chen, MPH, et al.
Published: (2023)

Successful treatment of Brunsting-Perry pemphigoid with dupilumab
by: Franklin R. Blum, BS, et al.
Published: (2021)

Successful treatment of cutaneous B-cell pseudolymphoma with photodynamic therapy
by: O. Yu Olisova, et al.
Published: (2020)

Cutaneous pseudolymphoma: A case report
by: Mayur Bhobe, et al.
Published: (2016)

Cutaneous pseudolymphoma: A case report
by: Mayur Bhobe, et al.
Published: (2016)

Effects of dupilumab on keloid stabilization and prevention
by: Ashley Wittmer, MSc, et al.
Published: (2023)

Lichen planus pemphigoides successfully treated with dupilumab
by: Peter Yi Ch'en, BS, et al.
Published: (2023)

Rapid resolution of widespread cutaneous lichen planus and generalized pruritus in an elderly patient following treatment with dupilumab
by: Soroush Kazemi, BS, et al.
Published: (2022)

Recalcitrant facial rash: Cutaneous coccidioidomycosis
by: Shanice A. McKenzie, BS, et al.
Published: (2020)

Treatment of Cutaneous Pseudolymphoma: A Systematic Review
by: Diana Miguel, et al.
Published: (2017)

Angioimmunoblastic T-cell lymphoma unmasked by treatment with dupilumab
by: Zi-Yi Choo, BS, et al.
Published: (2023)

Acceleration of cutaneous T-cell lymphoma following dupilumab administration
by: Kristen Russomanno, MD, et al.
Published: (2021)

VEXAS syndrome presenting as refractory cutaneous Kikuchi disease-like inflammatory pattern responding to tofacitinib
by: Lauren M. Fahmy, BS, et al.
Published: (2023)

Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab
by: Thomas Buttgereit, MD, et al.
Published: (2021)

Dupilumab-induced pityriasis rosea
by: Morgan Zabel, BS, et al.
Published: (2023)

Pseudolymphoma successfully treated by etretinate
by: Yuriko Iwahashi, et al.
Published: (2019)

Cutaneous Pseudolymphoma after COVID-19 Vaccine Injection
by: Júlia Verdaguer-Faja, et al.
Published: (2024)

Idiopathic cutaneous T‐cell pseudolymphoma with prominent granulomatous reaction
by: Yuki Iwai, et al.
Published: (2020)

Cutaneous pseudolymphoma: A clinicopathological study and immunohistochemical patterns
by: Fatemeh Sari Aslani, et al.
Published: (2021)

Ulcerative injection-site reaction associated with dupilumab therapy
by: Michael Phan, BS, et al.
Published: (2020)

A case report of uveitis secondary to dupilumab treatment for atopic dermatitis
by: Marissa Ayasse, BS, et al.
Published: (2021)

Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis
by: Eleanor Pope, BA, et al.
Published: (2022)